{"name":"Personalis","slug":"personalis","ticker":"PSNL","exchange":"NASDAQ","domain":"personalis.com","description":"The chief justice was the personal legal representative of the king of Hungary, who issued decrees of judicial character on behalf of the monarch authenticated with the royal seal, performed national notarial activities and played an important role in the organisation of lawyers training. Later the chief justice was the head of the Royal Court of Justice and the Tribunal of the Chief Justice, the highest legal forum of civil cases.","hq":"Fremont, CA","founded":0,"employees":"259","ceo":"Chris Hall","sector":"Genomics / Cancer Sequencing","stockPrice":6.65,"stockChange":0.26,"stockChangePercent":4.07,"marketCap":"$696M","metrics":{"revenue":69648000,"revenueGrowth":-24.9,"grossMargin":13.7,"rdSpend":50264000,"netIncome":-81270000,"cash":233218000,"dividendYield":0,"peRatio":-7.5,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Nektar Therapeutics' NKTR-214 patent cliff ($100M at risk)","drug":"Nektar Therapeutics' NKTR-214","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Personalis Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Personalis reported revenue of $123.8 million for the fourth quarter and $444.8 million for the full year 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Personalis Announces Collaboration with Bristol Myers Squibb to Develop Companion Diagnostics","summary":"Personalis will develop companion diagnostics for Bristol Myers Squibb's cancer therapies.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxNdzJhdEdMbDhFU1RtOHk4TXdWQmN6OXdjdm5BTVlHLThIV0UzV2VuNlNIUFAxdTc1N0p4eFQzMnJacTI0QUJPeHNIc19PVkprMGlFTnNCZUxSZElCRUxXWGdNT1phNFhNNG82b0sxbjk2RWxhYUpGUTQzV3FscVBjbWlGdllPV01EQnlNbV9VN2h0YU91MzVGaHc2bjBkQXlaZFcxTGl6V0M5ZWVqdFFIbkZ0WWJGamlmNXlTcVR6S25yOVR1ZFMtYjl3V1EzZkpaVkNMTzU0MA?oc=5","date":"2026-03-13","type":"pipeline","source":"The Globe and Mail","summary":"Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail","headline":"Wall Street Analysts Are Bullish on Top Healthcare Picks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNRDVIdGpIVDdnMlE3cTVZSVhPZEVUcG5ENU16T2gzM2k1RThNY1VvV1Y5d2FXaGJJcTFnaGtzTTlvMDhvZko0TWJfNExHaVdlT3pzTnk2ckRZOTUwb1lvWHo1bDlGczJsVDZpLW5GYm5ONmVHNEV0bHJfblV0LUYtNEtYSVRGaXNDRnVvRElDSjNHSHVnTE1OUzlnM1VmOG96S0hPSW9GVHhHTFczSnZYdENuRDdwQTJ5T3A0RTZ6elR5LUx4ckFzVTZB?oc=5","date":"2026-03-06","type":"earnings","source":"Trefis","summary":"Personalis Stock Pre-Market (-5.3%): FY26 Guidance Overshadows Q4 EPS Beat - Trefis","headline":"Personalis Stock Pre-Market (-5.3%): FY26 Guidance Overshadows Q4 EPS Beat","sentiment":"positive"},{"url":"https://news.google.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?oc=5","date":"2026-02-28","type":"pipeline","source":"simplywall.st","summary":"Personalis (PSNL) Losses Of US$81.3 Million Keep Bearish Narratives In Focus - simplywall.st","headline":"Personalis (PSNL) Losses Of US$81.3 Million Keep Bearish Narratives In Focus","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQZWY4cENNLXJCOF9kMFhHa3VWbl95V2hneW5XNmV0cGVIa0FaOUNJMWlWUEFzU0FWcjlYb2lmejN1V3RqWV9RMDhiZzRzcXV3YXRvZUlyS2puNmhqY1FpSkNUblBZVFFmU3RLU2QxVXRsMnJPM3ZQZ2drVWZ4VDBfdnNpSQ?oc=5","date":"2025-11-04","type":"earnings","source":"Yahoo Finance","summary":"Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance","headline":"Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPSll6Y240TG1JaXBmeDRuR1BLcnRieXM5Zzg5ajJYU0otS2M4blJWaWp3TzM4cUw4a0V6ZUxlMVhYclNYWUNLUUpITnJSd0N5LW55c1VjakdtcXpoNW5VZEg5S0NmRUd2cGlsdmktTVVGbnA0N2hjOXBPSnJ6WXVXYXpiUmlKVDdISlNtNFZ2UFQ2VVh2RUFwSEhyZjM4S2lqTEtONWhSV1RDUGJ3aXo3R01fVEJvNFI4Zk83YlFueVVaWVU?oc=5","date":"2025-09-11","type":"pipeline","source":"Seeking Alpha","summary":"Personalis' MRD Breakthrough Potential: Why I Hold Until Reimbursement Clarity Emerges - Seeking Alpha","headline":"Personalis' MRD Breakthrough Potential: Why I Hold Until Reimbursement Clarity Emerges","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-10","type":"pipeline","source":"simplywall.st","summary":"Is Personalis (NASDAQ:PSNL) A Risky Investment? - simplywall.st","headline":"Is Personalis (NASDAQ:PSNL) A Risky Investment?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-10","type":"pipeline","source":"simplywall.st","summary":"These Analysts Think Personalis, Inc.'s (NASDAQ:PSNL) Sales Are Under Threat - simplywall.st","headline":"These Analysts Think Personalis, Inc.'s (NASDAQ:PSNL) Sales Are Under Threat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQUkhXYVRVT2JEN080QTlQZklxUTUtSE5xOW1LXzViaVFqRXBrY2xHemFuNWZ5T2t5emlEaXpQRFRFWS1vbmIyQ1BfVmh6T09veWlrQjVHUFY2Q2xNakhULWwyNURWR044SDF3LURXNlFWdU1QWGtrckVYRC03azBBdnRqUF9yaW1xS0c0NkxYQVkyRWVFcG9kQnNB?oc=5","date":"2025-06-08","type":"pipeline","source":"Seeking Alpha","summary":"Personalis: Ultra-Sensitive Tech, Ultra-Sensitive Risks (NASDAQ:PSNL) - Seeking Alpha","headline":"Personalis: Ultra-Sensitive Tech, Ultra-Sensitive Risks (NASDAQ:PSNL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNM1RiOVA1blY2RlE0VU94TWRRNlg0LVZhTXktOGZSS1RwcGtZSVN3MnBSaGt0eGRNNmtzM0hkUjNmb0ZMUEtKMWxtMmROQ3o5ckE2d2g5TDdFRndKbGxwQ2c3MzlzZ3cwd1lsM3hwZ3p3anhiRlpGUGcwY1VIQXJsZEJEWURzZldUWWRTZy1oRXpHN1lnQm4zMW5FaUFmNDlHNjFuSA?oc=5","date":"2025-05-06","type":"trial","source":"Stock Titan","summary":"Personalis Reports Breakthrough Q1: 52% Test Growth Plus Perfect Cancer Detection Score in New Study - Stock Titan","headline":"Personalis Reports Breakthrough Q1: 52% Test Growth Plus Perfect Cancer Detection Score in New Study","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9LMXJvUzNtTlV6ZkVpRlk2Ui13SU9OdlJIM3ZpRE0zbXNIUlNRdG9na29xc185QkRHWXhIZWdSWUFPM2RFbWcwNnQxVU85MElhR3dv?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"PSNL Stock Price, News & Analysis | Personalis - Stock Titan","headline":"PSNL Stock Price, News & Analysis | Personalis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNQ3ZBUTRPcXJGcWF0d0JHR3RGX25DWkJlT2JuUzJzbU1sRnpzZEVYVXBjY2FNMmUzOWtRLU5GTjRWLW40VGpPek16TXV2c2dmeDdIWS12QUhsaEQ4U1lMa1hTTEJZQmE2Qk5QR3hOVUMyRkZ6OF80YmVEMEJ4OHVyQUxjNjNPMzE1TERZMTZBZmdUdE42SlE?oc=5","date":"2024-12-19","type":"deal","source":"Mugglehead Magazine","summary":"Personalis Inc share price jumps 50% on deals with Merck and Moderna - Mugglehead Magazine","headline":"Personalis Inc share price jumps 50% on deals with Merck and Moderna","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTFBOaUlRTHNsRWg1TE9fb3o1ZEhya0hkWVlXcXpyMmNHQTU0SDlzZFBOa08ySjZSTFlSMmpFYU1GblJITExyVkNudHBLaDBNYWxS?oc=5","date":"2024-01-11","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"Nektar Therapeutics' NKTR-214","drugSlug":"nktr-214","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Illumina","Invitae","Foundation Medicine"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":69648000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":69648000,"period":"2025-12-31"},{"value":84614000,"period":"2024-12-31"},{"value":84614000,"period":"2024-12-31"},{"value":73481000,"period":"2023-12-31"},{"value":73481000,"period":"2023-12-31"}],"grossProfit":15777000,"grossProfitHistory":[{"period":"2025-12-31","value":15777000},{"period":"2024-12-31","value":26825000},{"period":"2023-12-31","value":18208000},{"period":"2022-12-31","value":13350000}],"rdSpend":50264000,"rdSpendHistory":[{"period":"2025-12-31","value":50264000},{"period":"2024-12-31","value":48905000},{"period":"2023-12-31","value":64776000},{"period":"2022-12-31","value":64912000}],"sgaSpend":53570000,"operatingIncome":-88057000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-88057000},{"period":"2024-12-31","value":-68267000},{"period":"2023-12-31","value":-96294000},{"period":"2022-12-31","value":-115531000}],"netIncome":-81270000,"netIncomeHistory":[{"period":"2025-12-31","value":-81270000},{"period":"2024-12-31","value":-81284000},{"period":"2023-12-31","value":-108296000},{"period":"2022-12-31","value":-113315000}],"eps":-1.37,"epsHistory":[{"period":"2024-12-31","value":-1.37},{"period":"2023-12-31","value":-2.25},{"period":"2022-12-31","value":-2.48},{"period":"2021-12-31","value":-1.49}],"cash":124245000,"cashHistory":[{"period":"2025-12-31","value":124245000},{"period":"2024-12-31","value":91415000},{"period":"2023-12-31","value":56984000},{"period":"2022-12-31","value":89128000}],"totalAssets":334164000,"totalLiabilities":72979000,"totalDebt":39948000,"equity":261185000,"operatingCashflow":-74946000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-74946000},{"period":"2024-12-31","value":-45150000},{"period":"2023-12-31","value":-56258000},{"period":"2022-12-31","value":-70233000}],"capex":-4504000,"capexHistory":[{"period":"2025-12-31","value":-4504000},{"period":"2024-12-31","value":-1603000},{"period":"2023-12-31","value":-10911000},{"period":"2022-12-31","value":-49896000}],"freeCashflow":-79450000,"dividendsPaid":null,"buybacks":null,"employees":259,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":14094000,"ebit":-23738000,"ebitda":-21276000,"period":"2025-12-31","revenue":17345000,"epsBasic":-0.26,"netIncome":-23812000,"rdExpense":13072000,"epsDiluted":-0.26,"grossProfit":1900000,"operatingIncome":-25266000},{"sga":13034000,"ebit":-21585000,"ebitda":-19119000,"period":"2025-09-30","revenue":14495000,"epsBasic":-0.24,"netIncome":-21652000,"rdExpense":12171000,"epsDiluted":-0.24,"grossProfit":1914000,"operatingIncome":-23291000},{"sga":14179000,"ebit":-20006000,"ebitda":-17475000,"period":"2025-06-30","revenue":17203000,"epsBasic":-0.23,"netIncome":-20056000,"rdExpense":12381000,"epsDiluted":-0.23,"grossProfit":4756000,"operatingIncome":-21804000},{"sga":12263000,"ebit":-15715000,"ebitda":-13128000,"period":"2025-03-31","revenue":20605000,"epsBasic":-0.18,"netIncome":-15750000,"rdExpense":12640000,"epsDiluted":-0.18,"grossProfit":7207000,"operatingIncome":-17696000},{"sga":11168000,"ebit":-16422000,"ebitda":-13879000,"period":"2024-12-31","revenue":16800000,"epsBasic":-0.23,"netIncome":-16425000,"rdExpense":11494000,"epsDiluted":-0.23,"grossProfit":4550000,"operatingIncome":-18112000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":6.65,"previousClose":6.39,"fiftyTwoWeekHigh":11.5,"fiftyTwoWeekLow":3.84,"fiftyTwoWeekRange":"3.84 - 11.5","fiftyDayAverage":6.63,"twoHundredDayAverage":7.48,"beta":1.97,"enterpriseValue":474730816,"forwardPE":-7.5,"priceToBook":2.61,"priceToSales":10.79,"enterpriseToRevenue":7.36,"enterpriseToEbitda":-5.12,"pegRatio":0,"ebitda":-92692000,"ebitdaMargin":-143.7,"freeCashflow":-42353248,"operatingCashflow":-79463000,"totalDebt":38781000,"debtToEquity":15.2,"currentRatio":6.61,"returnOnAssets":-21.4,"returnOnEquity":-41.4,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":7,"targetMeanPrice":10.86,"targetHighPrice":13,"targetLowPrice":9,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":27,"institutionHeldPercent":60,"sharesOutstanding":104721098,"floatShares":68223701,"sharesShort":13104403,"shortRatio":7.19,"shortPercentOfFloat":12.5,"epsTrailing":-1.02,"epsForward":-0.89,"revenuePerShare":0.69,"bookValue":2.55,"officers":[{"age":56,"name":"Mr. Christopher M. Hall","title":"CEO & Director"},{"age":54,"name":"Dr. Richard  Chen M.D., M.S.","title":"Executive VP of R&D, President & Chief Medical Officer"},{"age":64,"name":"Mr. Aaron L. Tachibana","title":"CFO & COO"},{"age":null,"name":"Dr. Russ B. Altman M.D., Ph.D.","title":"Co-Founder and Member of Clinical & Scientific Advisory Board"},{"age":54,"name":"Dr. Euan Angus Ashley DPHIL, FRCP, M.D., Ph.D.","title":"Co-Founder and Member of Clinical & Scientific Advisory Board"},{"age":null,"name":"Dr. Michael P. Snyder Ph.D.","title":"Co-Founder and Member of Clinical & Scientific Advisory Board"},{"age":null,"name":"Mr. Ashish  Kheterpal","title":"Senior VP & Chief Information Officer"},{"age":53,"name":"Mr. Stephen M. Moore J.D.","title":"Senior VP, Chief Legal Officer & Corporate Secretary"}],"industry":"Diagnostics & Research","irWebsite":"","website":"https://www.personalis.com","phone":"650 752 1300"}}